No, ertapenem does NOT provide coverage against carbapenem-resistant Klebsiella pneumoniae or Enterococcus species
Ertapenem is completely ineffective against carbapenem-resistant organisms and has no activity against Enterococcus species, even when they are carbapenem-susceptible. This is a critical distinction that must be understood to avoid treatment failure and increased mortality.
Why Ertapenem Fails Against These Organisms
Carbapenem-Resistant Klebsiella pneumoniae (CRKP)
Ertapenem is hydrolyzed by carbapenemases, the enzymes that confer carbapenem resistance 1. When K. pneumoniae develops carbapenem resistance through mechanisms like:
- KPC (Klebsiella pneumoniae carbapenemase) - the most common type
- MBLs (metallo-β-lactamases) like NDM, VIM, IMP
- OXA-48-like enzymes
These enzymes rapidly degrade ertapenem, rendering it completely ineffective 2. In fact, ertapenem resistance often emerges before resistance to other carbapenems (imipenem/meropenem) because ertapenem has higher affinity for carbapenemases and is more easily hydrolyzed 3.
For carbapenem-resistant K. pneumoniae, the recommended first-line agents are:
- Ceftazidime-avibactam (for KPC-producers)
- Meropenem-vaborbactam (for KPC-producers)
- Imipenem-relebactam or cefiderocol as alternatives 2
Enterococcus Species
Ertapenem has NO intrinsic activity against Enterococcus species - this is a fundamental spectrum limitation 1, 4. The FDA label explicitly excludes Enterococcus from ertapenem's coverage 1. This is true regardless of whether the Enterococcus is vancomycin-susceptible or vancomycin-resistant.
For Enterococcus infections, appropriate agents include:
- Linezolid 600 mg IV/PO q12h (strong recommendation for enterococcal infections) 5
- High-dose daptomycin 8-12 mg/kg IV daily ± β-lactams for VRE bacteremia 5
- Ampicillin or amoxicillin for susceptible strains 5
Ertapenem's Actual Spectrum
Ertapenem is indicated ONLY for carbapenem-susceptible Enterobacteriaceae, including susceptible K. pneumoniae 6, 1. The 2019 Taiwan pneumonia guidelines note that ertapenem 1g daily was equivalent to ceftriaxone for community-acquired pneumonia due to susceptible Enterobacteriaceae including Klebsiella species 6.
Critical Clinical Pitfall
Using ertapenem for suspected or confirmed carbapenem-resistant organisms or Enterococcus infections will result in:
- Treatment failure
- Increased mortality (approximately one in three patients with CRKP die even with appropriate therapy 2)
- Delayed appropriate therapy, which significantly worsens outcomes 2
When carbapenem resistance is suspected or confirmed, rapid carbapenemase testing should be performed immediately to guide selection of novel β-lactam/β-lactamase inhibitor combinations 2. Time from blood culture to active antibiotic therapy directly influences mortality in critically ill patients with CRKP 2.